SCHEMBL2591233

SCHEMBL2591233

[CH2][CH]c1ccc(C(C)C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.58
MAPK1 P28482 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.46
GRIN2D O15399 2/20 0.44
GRIN3B O60391 2/20 0.44
GRIN1 Q05586 2/20 0.44
GRIN2A Q12879 2/20 0.44
GRIN2B Q13224 2/20 0.44
GRIN2C Q14957 2/20 0.44
GRIN3A Q8TCU5 2/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 2/20 0.41
PIM1 P11309 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
SIRT5 Q9NXA8 1/20 0.40
RAB9A P51151 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2086912 0.80 TYR (0.54) TYRMAPK1KDM4EALDH1A1GRIN2D
SCHEMBL2086915 0.80 TYR (0.54) TYRMAPK1KDM4EALDH1A1GRIN2D
SCHEMBL367595 0.79 TYR (0.58) TYRMAPK1KDM4EALDH1A1GRIN2D
SCHEMBL23918549 0.78 TYR (0.64) TYRMAPK1KDM4EALDH1A1GRIN2D
SCHEMBL30075786 0.78 TYR (0.64) TYRMAPK1KDM4EALDH1A1GRIN2D
SCHEMBL8073887 0.78 TYR (0.64) TYRMAPK1KDM4EALDH1A1GRIN2D
Methane SCHEMBL11025053 0.77 TYR (0.56) TYRMAPK1KDM4EALDH1A1GRIN2D
SCHEMBL104124 0.76 TYR (0.58) TYRMAPK1KDM4EALDH1A1PTGS1
SCHEMBL11458762 0.76 ALDH1A1 (0.47) ALDH1A1
SCHEMBL139407 0.76 TYR (0.61) TYRMAPK1KDM4EALDH1A1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2932973-B1 FORMULATIONS FOR USE IN THE TREATMENT OF SKIN CONDITIONS SOLIGENIX INC (US) 2020-04-01 EP disclosed
EP-2571507-B1 FORMULATIONS AND METHODS OF TREATMENT OF SKIN CONDITIONS SOLIGENIX INC (US) 2017-01-04 EP disclosed
EP-2932973-A1 FORMULATIONS FOR USE IN THE TREATMENT OF SKIN CONDITIONS Soligenix, Inc. (US) 2015-10-21 EP disclosed
US-20130211371-A1 FORMULATIONS AND METHODS OF TREATMENT OF SKIN CONDITIONS HY BIOPHARMA, INC. (US) 2013-08-15 US disclosed
EP-2571507-A1 FORMULATIONS AND METHODS OF TREATMENT OF SKIN CONDITIONS HY Biopharma Inc. (US) 2013-03-27 EP disclosed
WO-2011139558-A1 FORMULATIONS AND METHODS OF TREATMENT OF SKIN CONDITIONS HY BIOPHARMA, INC. (US) 2011-11-10 WO disclosed